2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 001

Longitudinal Cardiovascular Profiles of Youth with Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 002

Assessing Juvenile Idiopathic Arthritis Healthcare Costs to Advance Value-Based Care
Abstract Number: 003

Dysregulated Macrophage–Fibroblast Crosstalk Identified by Single-Cell RNA-seq in Juvenile Systemic Scleroderma Skin
Abstract Number: 004

Barriers and Facilitators to Teratogenicity Knowledge and Application among Adolescents and Young Adults with Rheumatic Disease
Abstract Number: 005

Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study
Abstract Number: 006

Age Matters: Clinical Profile and IVIG Responsiveness in infants with Kawasaki Disease. A multicentric retrospective analysis of 36 patients from North India
Abstract Number: 007

Subtle Signs, Severe Consequences: Clinical profile of infants with giant coronary aneurysms compared to those with normal coronaries. A multicentric retrospective analysis of infants with Kawasaki disease
Abstract Number: 008

Body Mass Index, Neighborhood Opportunity, and Outcomes of Childhood-Onset Lupus
Abstract Number: 009

Functional Lumen Imaging Probe (FLIP) for the Assessment of Esophageal Involvement in Juvenile Systemic Sclerosis: Characteristics and Clinical Utility
Abstract Number: 010

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 011

Lung Transplant for Pediatric Dermatomyositis Patients with Interstitial Lung Disease: A Single-Center Experience
Abstract Number: 012

Prevalence and Impact of Adverse Childhood Experiences in Pediatric Systemic Lupus Erythematosus
Abstract Number: 013

Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience
Abstract Number: 014

Bone Microarchitecture Impairment in Juvenile Systemic Lupus Erythematosus Patients: A Comparative Study
Abstract Number: 015

Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial

1
2
3
…
10
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].